已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

赛马鲁肽 恩帕吉菲 医学 2型糖尿病 二甲双胍 中止 随机对照试验 糖尿病 内科学 胃肠病学 泌尿科 利拉鲁肽 内分泌学
作者
Helena W. Rodbard,Julio Rosenstock,Luís Henrique Santos Canani,Chaicharn Deerochanawong,Janusz Gumprecht,Søren Lindberg,Ildiko Lingvay,ANETTE L. SØNDERGAARD,Marianne Bach Treppendahl,Eduard Montanya,Pablo Jordão Alcântara Cruz,Luis De Loredo,Cecilia Luquez,Maria Alejandra Moisello,Gustavo Akerman Augusto,Marise Lazaretti Castro,Luís Henrique Santos Canani,Branko Akrap,Tomislav Bulum,Dario Rahelić
出处
期刊:Diabetes Care [American Diabetes Association]
卷期号:42 (12): 2272-2281 被引量:314
标识
DOI:10.2337/dc19-0883
摘要

Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium-glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin.Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients.Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA1c versus empagliflozin at week 26 (treatment policy -1.3% vs. -0.9% [-14 vs. -9 mmol/mol], estimated treatment difference [ETD] -0.4% [95% CI -0.6, -0.3] [-5 mmol/mol (-6, -3)]; P < 0.0001). The treatment difference in HbA1c significantly favored oral semaglutide at week 26 for the trial product estimand (-1.4% vs. -0.9% [-15 vs. -9 mmol/mol], ETD -0.5% [95% CI -0.7, -0.4] [-6 mmol/mol (-7, -5)]; P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product -4.7 vs. -3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide.Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
开放又亦完成签到 ,获得积分10
2秒前
少川完成签到 ,获得积分10
3秒前
迟迟不吃吃完成签到 ,获得积分10
6秒前
无奈的盼望完成签到 ,获得积分10
6秒前
6秒前
9秒前
小蘑菇应助多年以后采纳,获得10
9秒前
10秒前
guo完成签到 ,获得积分10
11秒前
11秒前
1234发布了新的文献求助10
11秒前
14秒前
VIAI发布了新的文献求助10
15秒前
负责怀莲发布了新的文献求助10
17秒前
热心语柔完成签到 ,获得积分10
17秒前
多年以后发布了新的文献求助10
19秒前
19秒前
科研通AI5应助科研通管家采纳,获得10
19秒前
JamesPei应助科研通管家采纳,获得10
20秒前
20秒前
科研通AI5应助科研通管家采纳,获得10
20秒前
20秒前
李健应助科研通管家采纳,获得10
20秒前
20秒前
pan完成签到,获得积分10
21秒前
olivia完成签到,获得积分10
22秒前
缓慢安阳发布了新的文献求助10
24秒前
27秒前
28秒前
Rondab应助图南采纳,获得30
29秒前
1234发布了新的文献求助10
30秒前
深情安青应助小木安华采纳,获得10
31秒前
福大命大关注了科研通微信公众号
32秒前
淡定海亦发布了新的文献求助10
33秒前
暴躁的大侠完成签到,获得积分10
35秒前
35秒前
丘比特应助11采纳,获得10
36秒前
酷波er应助西瓜采纳,获得10
38秒前
淡定海亦完成签到,获得积分10
38秒前
超级飞侠完成签到,获得积分10
39秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989918
求助须知:如何正确求助?哪些是违规求助? 3532013
关于积分的说明 11255831
捐赠科研通 3270829
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882233
科研通“疑难数据库(出版商)”最低求助积分说明 809216